Table 3

Susceptibility of Carrion Crows to Experimental Infection with Lineage 1 and 2 West Nile Viruses

Stephanie M. Lim, Aaron C. Brault, Geert van Amerongen, Angela M. Bosco-Lauth, Hannah Romo, Varsha D. Sewbalaksing, Richard A. Bowen, Albert D.M.E. Osterhaus, Penelope Koraka¹, and Byron E.E. Martina¹

Author affiliations: Erasmus Medical Center, Rotterdam, the Netherlands (S.M. Lim, G. van Amerongen, V.D. Sewbalaksing, A.D.M.E. Osterhaus, P. Koraka, B.E.E. Martina); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (A.C. Brault, A.M. Bosco-Lauth, H. Romo); Colorado State University, Fort Collins (R.A. Bowen); Artemis One Health Research Institute, Utrecht, the Netherlands (A.D.M.E. Osterhaus, P. Koraka, B.E.E. Martina)

Main Article

Clinical profile of American crows experimentally infected with West Nile virus strains NY99-4132, Italy/2009/FIN, and Ita09

Virus group	No. died/no. total (%)	Median peak viremia, viral RNA/mL serum (range); no. birds	Median peak viremia, TCID₅₀/mL serum (range); no. birds*
NY99-4132	6/6 (100)	10^9.6 (10^9.1–10^10.1); 6	10^7.2 (10^4.7–10^7.2); 6
Italy/2009/FIN	0/5 (0)	10^1.0 (10^1.0–10^6.9); 5	10^1.8 (10^1.8–10^2.7); 5
Ita09	5/5 (100)	10^8.8 (10^8.0–10^9.1); 5	10^6.7 (10^6.0–10^7.5); 5
*Virus titers are expressed as log₁₀ 50% tissue culture infectious dose (TCID₅₀)/mL of serum.

Main Article

¹These authors contributed equally to this article.

Page created: July 14, 2015

Page updated: July 14, 2015

Page reviewed: July 14, 2015

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.